title: Lunelle monthly injectable contraceptive. An effective, safe, and convenient new birth control option.
abstract: Lunelle, an injectable estrogen/progestin contraceptive, is administered on a monthly basis and is now available as the first monthly injectable in the United States. International and US clinical trials have established its safety and confirmed its contraceptive efficacy. Fertility returns rapidly after discontinuation of injections. Studies have noted a high level of patient satisfaction with Lunelle, suggesting that monthly injectable contraception will become a first-line contraceptive option in the United States.
authors.affiliation: Department of Obstetrics and Gynecology, University of Florida, Jacksonville 32209, USA. andrew.kaunitz@jax.ufl.edu
authors.forename: A M
authors.initials: AM
authors.lastname: Kaunitz
mesh_terms: D003267:Contraception; D003271:Contraceptive Agents, Female / Q000008:administration & dosage* / Q000009:adverse effects; D004334:Drug Administration Schedule; D004958:Estradiol / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D005260:Female; D005298:Fertility / Q000187:drug effects; D006801:Humans; D007273:Injections, Intramuscular; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage* / Q000009:adverse effects; D017060:Patient Satisfaction; D011247:Pregnancy; D011374:Progesterone / Q000097:blood; D013997:Time Factors; D016896:Treatment Outcome; D014592:Uterine Hemorrhage
chemical_list: D003271:Contraceptive Agents, Female; C403500:Lunelle; D011374:Progesterone; D004958:Estradiol; D017258:Medroxyprogesterone Acetate